Corium International Inc (NASDAQ:CORI) has received a consensus recommendation of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $13.50.

Several equities research analysts recently issued reports on the company. Needham & Company LLC cut Corium International from a “buy” rating to a “hold” rating in a research note on Monday, October 15th. HC Wainwright cut Corium International from a “buy” rating to a “neutral” rating and set a $13.00 price target for the company. in a research note on Monday, October 15th. BidaskClub upgraded Corium International from a “sell” rating to a “hold” rating in a research note on Thursday, November 22nd. Finally, ValuEngine upgraded Corium International from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 12th.

Shares of CORI stock opened at $12.68 on Friday. The company has a debt-to-equity ratio of 2.83, a current ratio of 7.61 and a quick ratio of 7.47. The company has a market capitalization of $459.65 million, a P/E ratio of -7.73 and a beta of 0.87. Corium International has a 1 year low of $7.17 and a 1 year high of $13.93.

In other news, major shareholder Holding Co Gurnet acquired 36,629,505 shares of the stock in a transaction on Tuesday, November 27th. The stock was acquired at an average cost of $12.50 per share, for a total transaction of $457,868,812.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 30.80% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Man Group plc acquired a new position in shares of Corium International during the third quarter worth $163,000. Bamco Inc. NY increased its holdings in shares of Corium International by 138.0% during the third quarter. Bamco Inc. NY now owns 291,474 shares of the biopharmaceutical company’s stock worth $2,772,000 after buying an additional 169,000 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Corium International by 0.3% during the third quarter. Franklin Resources Inc. now owns 2,065,461 shares of the biopharmaceutical company’s stock worth $19,642,000 after buying an additional 5,901 shares in the last quarter. Bridgeway Capital Management Inc. acquired a new position in shares of Corium International during the third quarter worth $1,399,000. Finally, BlackRock Inc. increased its holdings in shares of Corium International by 1.2% during the third quarter. BlackRock Inc. now owns 2,242,514 shares of the biopharmaceutical company’s stock worth $21,326,000 after buying an additional 26,752 shares in the last quarter.

About Corium International

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Further Reading: What is a Fiduciary?

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.